AstraZeneca/$AZN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Ticker

$AZN
Sector
Primary listing

Employees

94,300

AstraZeneca Metrics

BasicAdvanced
$248B
14.99
$5.31
0.15
$1.54
1.27%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.

Bulls say / Bears say

AstraZeneca’s second-quarter 2025 revenue rose 11% year-on-year to $14.46 billion, with core EPS of $2.17 per share both surpassing analyst expectations and leading the company to reaffirm its full-year guidance. (Reuters)
The company’s oncology portfolio, representing nearly half of total revenue, grew 18% to $6.31 billion, driven by strong demand for Tagrisso, Lynparza, and Imfinzi, underscoring the strength of its core therapeutic area. (Reuters)
AstraZeneca plans to file for regulatory approval of its novel hypertension drug Baxdrostat by year-end 2025, targeting 2026 U.S. and EU approvals and anticipating peak annual sales exceeding $5 billion, diversifying its portfolio beyond oncology. (Reuters)
CEO Pascal Soriot noted the company’s proposals to cut U.S. drug prices and looming threats of tariffs and Most Favoured Nation pricing under the Trump administration underscore persistent pricing and trade uncertainties that could compress margins. (Reuters)
A unit of AstraZeneca faces a proposed class action accusing it of maintaining a Soliris monopoly through fraudulently obtained patents, alleging billions in overcharges to payers and exposing the firm to significant litigation risk. (Bloomberg Law)
AstraZeneca has postponed the Phase III AVANZAR lung cancer trial readout to the first half of 2026, potentially delaying revenue contributions from this key program. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.

AstraZeneca Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AstraZeneca Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AZN

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs